Table 2 Patient characteristics.

n

12

10

M/F

6/6

6/4

Weight (kg)

83.2 ± 3.7

85.5 ± 5.9

Age

48.1 ± 2.7

49.1 ± 2.7

Height (cm)

177.8 ± 2.8

177.4 ± 3.3

Pulmonary involvement

10/12

9/10

Fatigue

12/12

10/10

Use of nonsteroidal antiinflammatory drugs (NSAIDs)

2/12

1/10

Use of psychological drugs

2/12

2/10

Use of oral steroids

4/12

2/10

Use of opioids

1/12

0/10

Use of analgesics

2/12

2/10

Use of anticonvulsants

3/12

3/10

Use of systemic antiinflammatory drug

1/12

2/10

Currently smoking

2/12

2/10

ARA 290 dose (µg/kg)

24.6 ± 1.1

0

ARA 290 dose (µg/m²)

997.1 ± 26.9

0

C-reactive protein (pretreatment versus

3.0 ± 1 versus

3.7 ± 1.5 versus

posttreatment; NS)

3.1 ± 1.2

4.1 ± 1.6

SFNSL score (pretreatment versus

41.0 ± 4.6 versus

30.6 ± 4.2 versus

posttreatment; p < 0.05)

29.8 ± 3.5

26.2 ± 4.0

BPI mean score (pretreatment versus

7.1 ± 0.2 versus

6.2 ± 0.9 versus

posttreatment; NS)

4.8 ± 0.4

4.1 ± 0.3

SF-36 mean score (pretreatment versus

37.6 ± 2.8 versus

44.5 ± 2.8 versus

posttreatment; NS)

50.7 ± 3.1

52.3 ± 3.1

FAS (pretreatment versus posttreatment; NS)

37.9 ± 2.6 versus

33.6 ± 2.3 versus

33.3 ± 2.8

29.8 ± 3.3

IDS (pretreatment versus posttreatment; NS)

28.7 ± 4.9 versus

24.1 ± 4.3 versus

24.7 ± 4.2

22.1 ± 4.3